Numerous biotechs have brought onboard further experience at leadership level, with several seeking guidance on lead candidates.
As biotechs bring lead drug candidates closer to approval, they often need to add greater clinical expertise or require further funds to progress deeper into trials. In May, appointments that were designed to help on of both these fronts were seen across the industry.
At the larger end of the biotech scale, Genentech brought in a new head of research with a background in computational biology – aiming to drive a more data-based approach to drug discovery.
For this appointment and more, click through the slideshow above.